Evvy, a NYC-based startup providing women’s healthcare through biomarker discovery, raised $14M in Series A funding.
The round was led by Left Lane Capital, with participation from General Catalyst, Labcorp Venture Fund, RH Capital, Ingeborg Investments, G9 Ventures, Virtue, and Amboy Street Ventures.
The company intends to use the funds to scale access to its testing & care platform, leverage AI to discover novel molecular signatures for women’s health diagnostics, and validate improved outcomes in fertility, pregnancy, and beyond.
Founded by Priyanka Jain, Laine Bruzek, and Pita Navarro, Evvy provides an at-home vaginal microbiome test to use metagenomic sequencing. Insights from their test led to the expansion of its vaginal health platform, which now brings together testing, precision care, and proactive tracking to give women and people with vaginas the healthcare they deserve. Through it, Evvy is building the real-world datasets necessary to improve health conditions in the female body. For eligible tests, the company also offers clinically-validated integrative prescription treatment programs to improve the vaginal microbiome.
Today, the company is also announcing the addition of STI and antibiotic resistance testing as an add-on PCR panel to its Vaginal Health Test. The PCR panel will screen for a range of common sexually transmitted infections including chlamydia, gonorrhea, trichomoniasis, and more. It also identifies the presence of 11 vaginal microbes, similar to a standard vaginitis PCR test offered at doctor’s offices, and 17 antibiotic-resistance genes. All PCR results are returned within three business days, with options for immediate STI treatment prescriptions when necessary.
Once full metagenomic sequencing results are ready, Evvy compiles all test data into a cohesive results experience along with a custom plan with clear next steps, science-backed education, and free 1:1 coaching. For eligible tests, Evvy also offers clinically-validated integrative prescription treatment programs to improve the vaginal microbiome.
FinSMEs
27/09/2023